PDP1 and cancer: Association of expression of distinct PDK with poor prognosis and resistance to anti-cancer therapies is documented, and PDK pharmacological inhibition (which results in PDH activation) constitutes a potentially operative therapy in several cancer types, including renal cancer23,24,27.